Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics and psychiatric morbidity

From: Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study

Age, mean (range) 58 (44–67)
Male sex, n (%) 9 (53)
BMI, mean (range) 27.2 (17.5–35.6)
HCV RNA IE/mL, median (range) 2.6 × 106 (2.8 × 105 - 16 × 106)
HCV genotype, n (%)
 1a 7 (41)
 1b 3 (18)
 3a 5 (29)
 1a/1b/1× 2 (12)
Descent
 European 16 (94)
 Middle Eastern 1 (6)
Previous IFN treatment, n (%) 11 (65)
 Psychiatric side effects during IFN treatment, n 6  
Liver cirrhosis, n (%) 10 (59)
 Child-Pugh A 9  
 Child-Pugh B 1  
Current psychiatric morbidity, n (%) 6 (35)
 Any mood disorder 4 (24)
 Any substance abuse or dependencea 2 (12)
 Any anxiety disorder 1 (6)
 ADHDc 2 (12)
Lifetime psychiatric morbidity, n (%) 15 (88)
 Any mood disorder 10 (59)
 Any psychotic disorderb 1 (6)
 Any substance abuse or dependence 11 (65)
 Any anxiety disorder 6 (35)
 Any eating disorder 2 (12)
 ADHDc 2 (12)
Psychotropic medication
 Any psychotropic medication 8 (47)
 Antidepressants 3 (18)
 Benzodiazepines 3 (18)
 Benzodiazepine-like agents for sleep 3 (18)
 Central nervous system stimulants 1 (6)
 Buprenorphine 2 (12)
  1. a Patients were in an opiate substitution treatment programme
  2. b Substance-induced psychotic disorder
  3. c ADHD, attention-deficit/hyperactivity disorder based on patient diagnosis in medical records